K. Nolan

发表

Catechol O-methyltransferase Val158Met polymorphism in schizophrenia: differential effects of Val and Met alleles on cognitive stability and flexibility.

Robert M Bilder, R. Bilder, J. Volavka, 2004, The American journal of psychiatry.

Characteristics of assaultive behavior among psychiatric inpatients.

P. Czobor, J. Volavka, K. Nolan, 2003, Psychiatric services.

Overt Aggression and Psychotic Symptoms in Patients With Schizophrenia Treated With Clozapine, Olanzapine, Risperidone, or Haloperidol

J. Lieberman, P. Czobor, J. McEvoy, 2004, Journal of clinical psychopharmacology.

Modality-independent impairments in word processing in a deep dyslexic patient

Alfonso Caramazza, A. Caramazza, K. Nolan, 1982, Brain and Language.

Generation of renal Epo-producing cell lines by conditional gene tagging reveals rapid HIF-2 driven Epo kinetics, cell autonomous feedback regulation, and a telocyte phenotype.

R. Wenger, K. Nolan, W. Qi, 2019, Kidney international.

A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease

Gastone G. Celesia, David A. Bennett, Norman L. Foster, 1994 .

Analysis of polymorphisms in AT‐rich domains of neuregulin 1 gene in schizophrenia

Kenny Q. Ye, K. Nolan, H. Lachman, 2006, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

Rare NRXN1 promoter variants in patients with schizophrenia

J. Locker, K. Nolan, H. Lachman, 2010, Neuroscience Letters.

Implicit emotion perception in schizophrenia.

D. Javitt, A. Todorov, P. Butler, 2015, Journal of psychiatric research.

Hypoxia: from basic mechanisms to therapeutics – a meeting report on the Keystone and HypoxiaNet Symposium

K. Nolan, Carsten C. Scholz, 2015, Hypoxia.

Neurogenic and pericytic plasticity of conditionally immortalized cells derived from renal erythropoietin‐producing cells

T. Knöpfel, R. Wenger, K. Nolan, 2022, Journal of cellular physiology.

Source and microenvironmental regulation of erythropoietin in the kidney

R. Wenger, K. Nolan, 2018, Current opinion in nephrology and hypertension.

The Role of Prefrontal Abnormalities in Schizophrenia

M. Hoptman, K. Nolan, 2009 .

Analysis of a Promoter Polymorphism in the SMDF Neuregulin 1 Isoform in Schizophrenia

K. Nolan, H. Lachman, P. Stopkova, 2009, Neuropsychobiology.

Reducing Inpatient Aggression: Does Paying Attention Pay Off?

K. Nolan, L. Citrome, 2008, Psychiatric Quarterly.

Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms

D. Javitt, E. Petkova, M. Epstein, 2018, Schizophrenia Research.

White matter in the elderly

J. Blass, K. Nolan, 1990, Neurology.

Suicidal behavior in patients with schizophrenia is related to COMT polymorphism

M. Karvonen, P. Czobor, J. Tiihonen, 2000, Psychiatric genetics.

Delirium: Phenomenology and Diagnosis—A Neurobiologic View

R. Black, J. Blass, K. Nolan, 1991, International Psychogeriatrics.

Preventing cognitive decline.

J. Blass, K. Nolan, John P. Blass, 1992, Clinics in geriatric medicine.

Negative Cooperativity in NAD(P)H Quinone Oxidoreductase 1 (NQO1)

D. Timson, A. Gutiérrez, I. Stratford, 2019, Chembiochem : a European journal of chemical biology.

Catechol-O-methyltransferase and monoamine oxidase-A polymorphisms and treatment response to typical and atypical neuroleptics.

J. Lieberman, P. Czobor, J. Volavka, 2006, Journal of clinical psychopharmacology.

Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2.

I. Stratford, K. Nolan, R. Bryce, 2010, Bioorganic & medicinal chemistry letters.

Inhibitors of NQO1: identification of compounds more potent than dicoumarol without associated off-target effects.

I. Stratford, K. Nolan, K. Scott, 2011, Biochemical pharmacology.

An association between a polymorphism of the tryptophan hydroxylase gene and aggression in schizophrenia and schizoaffective disorder

J. Volavka, K. Nolan, H. Lachman, 2000, Psychiatric genetics.

Atypical Antipsychotics, Neurocognitive Deficits, and Aggression in Schizophrenic Patients

P. Czobor, K. Nolan, M. Krakowski, 2008, Journal of clinical psychopharmacology.

Analysis of protocadherin alpha gene enhancer polymorphism in bipolar disorder and schizophrenia

Y. Lo, K. Nolan, H. Lachman, 2008, Schizophrenia Research.

Disturbances in Response Inhibition and Emotional Processing as Potential Pathways to Violence in Schizophrenia: A High-Density Event-Related Potential Study.

John J. Foxe, P. Czobor, M. Hoptman, 2016, Schizophrenia bulletin.

Non-symmetrical furan-amidines as novel leads for the treatment of cancer and malaria.

I. Stratford, Soraya Alnabulsi, K. Nolan, 2016, European journal of medicinal chemistry.

Coumarin-based inhibitors of human NAD(P)H:quinone oxidoreductase-1. Identification, structure-activity, off-target effects and in vitro human pancreatic cancer toxicity.

D. Timson, I. Stratford, D. Ross, 2007, Journal of medicinal chemistry.

Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1).

M. Dunstan, I. Stratford, D. Ross, 2009, Journal of medicinal chemistry.

Triazoloacridin-6-ones as novel inhibitors of the quinone oxidoreductases NQO1 and NQO2.

I. Stratford, K. Nolan, R. Bryce, 2010, Bioorganic & medicinal chemistry.

The relationship between history of violent and criminal behavior and recognition of facial expression of emotions in men with schizophrenia and schizoaffective disorder

Ruben C. Gur, Raquel E. Gur, Margarete Delazer, 2006 .

Lipoxins attenuate renal fibrosis by inducing let-7c and suppressing TGFβR1.

E. Brennan, K. Nolan, A. Maxwell, 2013, Journal of the American Society of Nephrology : JASN.

Induction of long noncoding RNA MALAT1 in hypoxic mice

R. Wenger, K. Nolan, H. H. Marti, 2015, Hypoxia.

Catecholamines and Aggression: The Role of COMT and MAO Polymorphisms

R. Bilder, J. Volavka, K. Nolan, 2004, Annals of the New York Academy of Sciences.

Aggressive behavior in schizophrenia is associated with the low enzyme activity COMT polymorphism: A replication study

K. Nolan, H. Lachman, R. Strous, 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

Association between catechol O-methyltransferase genotype and violence in schizophrenia and schizoaffective disorder.

J Volavka, J. Volavka, K. Nolan, 1998, The American journal of psychiatry.

Different subpopulations of kidney interstitial cells produce erythropoietin and factors supporting tissue oxygenation in response to hypoxia in vivo.

R. Wenger, K. Nolan, R. Kramann, 2020, Kidney international.

REST is a hypoxia-responsive transcriptional repressor

K. J. Murphy, A. Cheong, K. Nolan, 2016, Scientific Reports.

Staff and Patient Views of the Reasons for Aggressive Incidents: A Prospective, Incident-Based Study

J. Volavka, K. Nolan, L. Citrome, 2009, Psychiatric Quarterly.

Paricalcitol protects against TGF-β1-induced fibrotic responses in hypoxia and stabilises HIF-α in renal epithelia.

E. Brennan, K. Nolan, C. Taylor, 2015, Experimental cell research.

Analysis of protocadherin alpha gene deletion variant in bipolar disorder and schizophrenia

K. Nolan, H. Lachman, P. Stopkova, 2008, Psychiatric genetics.

Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder.

J. Lieberman, P. Czobor, J. McEvoy, 2005, Journal of psychiatric research.

Methodological Structure for Aggression Research

J. Volavka, K. Nolan, 2008, Psychiatric Quarterly.

Novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2): crystal structures, biochemical activity, and intracellular effects of imidazoacridin-6-ones.

M. Dunstan, I. Stratford, K. Nolan, 2011, Journal of medicinal chemistry.

FIH Regulates Cellular Metabolism through Hydroxylation of the Deubiquitinase OTUB1

A. von Kriegsheim, R. Wenger, D. Peet, 2016, PLoS biology.

Positive association of schizophrenia to JARID2 gene

Kenny Q. Ye, K. Nolan, H. Lachman, 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

Behavioral validation of avolition in schizophrenia

D. Javitt, F. Trémeau, D. Malaspina, 2012, Schizophrenia Research.

Self-report and laboratory measures of impulsivity in patients with schizophrenia or schizoaffective disorder and healthy controls

M. Hoptman, Deb D'Angelo, K. Nolan, 2011, Psychiatry Research.

Failure of CT Scan to Detect Ischemic Lesions in Patients With Dementia

J. Blass, K. Nolan, A. Kurita, 1993, Journal of geriatric psychiatry and neurology.

The two common polymorphic forms of human NRH-quinone oxidoreductase 2 (NQO2) have different biochemical properties

D. Timson, I. Stratford, K. Nolan, 2014, FEBS letters.

Differential effect of catechol-O-methyltransferase Val158Met genotype on emotional recognition abilities in healthy men and women

Herbert Oberacher, Georg Kemmler, Walther Parson, 2007, Journal of the International Neuropsychological Society.

Absence of Vascular Dementia in an Autopsy Series from a Dementia Clinic

J. Blass, K. Nolan, A. Seligmann, 1998, Journal of the American Geriatrics Society.

Unconscious perception of meaning: A failure to replicate

A. Caramazza, K. Nolan, 1982 .

Adolescent Cannabis Use, Psychosis and Catechol-O-Methyltransferase Genotype in African Americans and Caucasians

S. Sen, K. Nolan, H. Lachman, 2009, Psychiatric Quarterly.

Pentoxifylline in Cerebrovascular Dementia

J. Blass, K. Nolan, L. Barclay, 1992, Journal of the American Geriatrics Society.

In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2).

Hoda Abdel-Aal Bettley, I. Stratford, K. Nolan, 2010, Bioorganic & medicinal chemistry letters.

Psychopathy and violent behavior among patients with schizophrenia or schizoaffective disorder.

P. Czobor, J. Volavka, K. Nolan, 1999, Psychiatric services.

Scopolamine-induced impariment as a potential predictor of Alzheimer's Disease in individuals with Apolipoprotein E type 4 alleles

N. Pomara, K. Nolan, Glenn Halpern, 1995, Neurochemical Research.

Neurophysiological Effects of Bitopertin in Schizophrenia

D. Javitt, E. Petkova, K. Nolan, 2017, Journal of clinical psychopharmacology.

Pharmacological inhibitors of NAD(P)H quinone oxidoreductase, NQO1: structure/activity relationships and functional activity in tumour cells.

I. Stratford, K. Nolan, K. Scott, 2010, Biochemical pharmacology.

Gender differences in facial emotion recognition in persons with chronic schizophrenia

Margarete Delazer, James Loughead, C. Kohler, 2007, European Psychiatry.

In Silico Screening Reveals Structurally Diverse, Nanomolar Inhibitors of NQO2 That Are Functionally Active in Cells and Can Modulate NF-κB Signaling

Mark S Dunstan, David Leys, M. Dunstan, 2011, Molecular Cancer Therapeutics.

What can the study of first impressions tell us about attitudinal ambivalence and paranoia in schizophrenia?

D. Javitt, A. Todorov, P. Butler, 2016, Psychiatry Research.

Aberrant response inhibition and task switching in psychopathic individuals

John J. Foxe, Pierfilippo De Sanctis, P. Czobor, 2015, Psychiatry Research.

The neuronal oxygen‐sensing pathway controls postnatal vascularization of the murine brain

R. Wenger, K. Nolan, H. H. Marti, 2019, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility

P. Czobor, J. Volavka, K. Nolan, 2007, International clinical psychopharmacology.

Immediate affective motivation is not impaired in schizophrenia

D. Javitt, P. Butler, F. Trémeau, 2014, Schizophrenia Research.

The Continuum of Deep/Surface Dyslexia

B. Volpe, K. Nolan, L. Burton, 1997, Journal of psycholinguistic research.

Public-academic partnerships: integrating state psychiatric hospital treatment and clinical research.

J. Levine, F. Trémeau, K. Nolan, 2008, Psychiatric services.

Relationship between Cognitive Status and Behavioral Symptoms in Alzheimer's Disease and Mixed Dementia

J. Blass, K. Nolan, A. Kurita, 1993, Journal of the American Geriatrics Society.

Annual Conference of the Swiss Society of Sleep Research, Sleep Medicine and Chronobiology (SSSSC) and the Swiss Society of Biological Psychiatry (SSBP). Sleepless Mind. Mindless Sleep? Bern, March 25 and 26, 2009

T. Hansen, K. D. Jakobsen, J. Amsterdam, 2009, Neuropsychobiology.

Incidence of the Fuld WAIS-R profile in traumatic brain injury and Parkinson's disease.

K. Nolan, L. Burton, 1998, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.

In reply

J. Blass, K. Nolan, 1999 .

A trial of thiamine in Alzheimer's disease.

J. Langberg, R. Black, J. Blass, 1991, Archives of neurology.

COMT158 polymorphism and hostility

Brian Sheitman, Jeffrey A Lieberman, Leslie Citrome, 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation

J. Lieberman, P. Czobor, J. Volavka, 2005, Schizophrenia Research.

In silico identification and biochemical characterization of novel inhibitors of NQO1.

Richard A Bryce, D. Timson, I. Stratford, 2006, Bioorganic & medicinal chemistry letters.

Hypoxia: from basic mechanisms to therapeutics – a meeting report on the Keystone and HypoxiaNet Symposium

K. Nolan, Carsten C. Scholz, 2015, Hypoxia.